Adjunctive statin therapy reduces intracranial hemorrhage and 1-year mortality in patients with atrial fibrillation after acute ischemic stroke: A population-based epidemiological study from Taiwan
| Autor: | Ben-Chung Cheng, Hung-Chen Wang, Chia-Te Kung, Wei-Che Lin, Nai-Wen Tsai, Jr-Rung Lin, Cheng-Hsien Lu, Hui-Chen Lin, Chih-Cheng Huang, Wen-Neng Chang, Yu-Jih Su, Wan-Chen Tsai, Chih-Min Su |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
medicine.medical_specialty Statin medicine.drug_class Taiwan Lower risk Brain Ischemia Coronary artery disease 03 medical and health sciences 0302 clinical medicine Physiology (medical) Internal medicine Atrial Fibrillation Epidemiology Odds Ratio medicine Humans cardiovascular diseases Stroke Aged Retrospective Studies business.industry nutritional and metabolic diseases Atrial fibrillation General Medicine Odds ratio Middle Aged medicine.disease Confidence interval Neurology 030220 oncology & carcinogenesis Female lipids (amino acids peptides and proteins) Surgery Neurology (clinical) Hydroxymethylglutaryl-CoA Reductase Inhibitors business Intracranial Hemorrhages 030217 neurology & neurosurgery |
| Zdroj: | Journal of Clinical Neuroscience. 69:224-229 |
| ISSN: | 0967-5868 |
| Popis: | Atrial fibrillation (AF)-related stroke causes severe disability and poor prognosis. Adjunctive statin therapy has been recommended for atherosclerotic-related stroke but not AF-related stroke. This study investigated the effects of statin in AF patients who experienced acute ischemic stroke.Data from patients with AF experiencing first-ever ischemic stroke between 2001 and 2010 were collected from the Taiwan National Health Insurance Research Database and categorized into non-statin and statin groups. The statin group was further divided into pre-stroke statin (those who began statin therapy before stroke) and post-stroke statin (those who began statin therapy after stroke) groups. The risks for recurrent ischemic stroke, coronary artery disease (CAD), intracranial hemorrhage (ICH), and 1-year mortality were compared among the groups.A total of 43,242 patients were in the non-statin, 2858 in the pre-stroke statin and 4640 in post-stroke statin groups. Comparing the risk for recurrent stroke and CAD among the three groups, the pre-stroke statin and post-stroke statin groups did not exhibit a significant difference compared with the non-statin group. In terms of ICH risk, the statin group had a lower risk for ICH (odds ratio [OR] 0.79, 95% confidence interval [CI] 0.68-0.90; p = 0.0007) compared with the non-statin group. The overall 1-year mortality in both statin subgroups was lower than that in the non-statin group (pre-stroke statin, OR 0.55 [95% CI 0.49-0.61]; p 0.0001 versus post-stroke statin, OR 0.53 [95% CI 0.48-0.58]; p 0.0001).Statin therapy reduced the risk of ICH and 1-year mortality in AF patients who experienced acute ischemic stroke. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect